The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Tardive Dyskinesia (TD) Treatment Drugs Market Research Report 2024
Synopsis
Tardive dyskinesia is a type of neurological disorder, which characterized the blink your eyes fast, chew, smack or pucker of lips, puff out your cheeks, tongue and others. The patients treating with neuroleptic drugs or anti-psychotic medications can also be the cause of tardive dyskinesia. Tardive dyskinesia is difficult to treat as treatment process is also not confirmed and the drug is also not approved in various conditions. The treatment of tardive dyskinesia is directly affect the neurological system of the respective patients. This disorder may commonly occurs in smoker than non-smoker, and also in the patient of depression, anxiety disorder and others.
The global Tardive Dyskinesia (TD) Treatment Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tardive Dyskinesia (TD) Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tardive Dyskinesia (TD) Treatment Drugs.
Report Scope
The Tardive Dyskinesia (TD) Treatment Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tardive Dyskinesia (TD) Treatment Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tardive Dyskinesia (TD) Treatment Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Neurocrine Biosciences, Inc.
Teva Pharmaceutical Industries
Pfizer Inc.
Biogen
Novartis AG
AstraZeneca
GlaxoSmithKline plc.
Bayer AG
Sanofi
Segment by Type
Valbenazine
Deutetrabenazine
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tardive Dyskinesia (TD) Treatment Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Tardive dyskinesia is a type of neurological disorder, which characterized the blink your eyes fast, chew, smack or pucker of lips, puff out your cheeks, tongue and others. The patients treating with neuroleptic drugs or anti-psychotic medications can also be the cause of tardive dyskinesia. Tardive dyskinesia is difficult to treat as treatment process is also not confirmed and the drug is also not approved in various conditions. The treatment of tardive dyskinesia is directly affect the neurological system of the respective patients. This disorder may commonly occurs in smoker than non-smoker, and also in the patient of depression, anxiety disorder and others.
The global Tardive Dyskinesia (TD) Treatment Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tardive Dyskinesia (TD) Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tardive Dyskinesia (TD) Treatment Drugs.
Report Scope
The Tardive Dyskinesia (TD) Treatment Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tardive Dyskinesia (TD) Treatment Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tardive Dyskinesia (TD) Treatment Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Neurocrine Biosciences, Inc.
Teva Pharmaceutical Industries
Pfizer Inc.
Biogen
Novartis AG
AstraZeneca
GlaxoSmithKline plc.
Bayer AG
Sanofi
Segment by Type
Valbenazine
Deutetrabenazine
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tardive Dyskinesia (TD) Treatment Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Valbenazine
1.2.3 Deutetrabenazine
1.3 Market by Application
1.3.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Perspective (2019-2030)
2.2 Tardive Dyskinesia (TD) Treatment Drugs Growth Trends by Region
2.2.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Tardive Dyskinesia (TD) Treatment Drugs Historic Market Size by Region (2019-2024)
2.2.3 Tardive Dyskinesia (TD) Treatment Drugs Forecasted Market Size by Region (2025-2030)
2.3 Tardive Dyskinesia (TD) Treatment Drugs Market Dynamics
2.3.1 Tardive Dyskinesia (TD) Treatment Drugs Industry Trends
2.3.2 Tardive Dyskinesia (TD) Treatment Drugs Market Drivers
2.3.3 Tardive Dyskinesia (TD) Treatment Drugs Market Challenges
2.3.4 Tardive Dyskinesia (TD) Treatment Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tardive Dyskinesia (TD) Treatment Drugs Players by Revenue
3.1.1 Global Top Tardive Dyskinesia (TD) Treatment Drugs Players by Revenue (2019-2024)
3.1.2 Global Tardive Dyskinesia (TD) Treatment Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tardive Dyskinesia (TD) Treatment Drugs Revenue
3.4 Global Tardive Dyskinesia (TD) Treatment Drugs Market Concentration Ratio
3.4.1 Global Tardive Dyskinesia (TD) Treatment Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tardive Dyskinesia (TD) Treatment Drugs Revenue in 2023
3.5 Tardive Dyskinesia (TD) Treatment Drugs Key Players Head office and Area Served
3.6 Key Players Tardive Dyskinesia (TD) Treatment Drugs Product Solution and Service
3.7 Date of Enter into Tardive Dyskinesia (TD) Treatment Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tardive Dyskinesia (TD) Treatment Drugs Breakdown Data by Type
4.1 Global Tardive Dyskinesia (TD) Treatment Drugs Historic Market Size by Type (2019-2024)
4.2 Global Tardive Dyskinesia (TD) Treatment Drugs Forecasted Market Size by Type (2025-2030)
5 Tardive Dyskinesia (TD) Treatment Drugs Breakdown Data by Application
5.1 Global Tardive Dyskinesia (TD) Treatment Drugs Historic Market Size by Application (2019-2024)
5.2 Global Tardive Dyskinesia (TD) Treatment Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size (2019-2030)
6.2 North America Tardive Dyskinesia (TD) Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2019-2024)
6.4 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size (2019-2030)
7.2 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2019-2024)
7.4 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size (2019-2030)
8.2 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market Size (2019-2030)
9.2 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2019-2024)
9.4 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market Size (2019-2030)
10.2 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Tardive Dyskinesia (TD) Treatment Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Neurocrine Biosciences, Inc.
11.1.1 Neurocrine Biosciences, Inc. Company Detail
11.1.2 Neurocrine Biosciences, Inc. Business Overview
11.1.3 Neurocrine Biosciences, Inc. Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.1.4 Neurocrine Biosciences, Inc. Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.1.5 Neurocrine Biosciences, Inc. Recent Development
11.2 Teva Pharmaceutical Industries
11.2.1 Teva Pharmaceutical Industries Company Detail
11.2.2 Teva Pharmaceutical Industries Business Overview
11.2.3 Teva Pharmaceutical Industries Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.2.4 Teva Pharmaceutical Industries Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.2.5 Teva Pharmaceutical Industries Recent Development
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Detail
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.3.4 Pfizer Inc. Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.3.5 Pfizer Inc. Recent Development
11.4 Biogen
11.4.1 Biogen Company Detail
11.4.2 Biogen Business Overview
11.4.3 Biogen Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.4.4 Biogen Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.4.5 Biogen Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.5.4 Novartis AG Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.5.5 Novartis AG Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.6.4 AstraZeneca Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.6.5 AstraZeneca Recent Development
11.7 GlaxoSmithKline plc.
11.7.1 GlaxoSmithKline plc. Company Detail
11.7.2 GlaxoSmithKline plc. Business Overview
11.7.3 GlaxoSmithKline plc. Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.7.4 GlaxoSmithKline plc. Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.7.5 GlaxoSmithKline plc. Recent Development
11.8 Bayer AG
11.8.1 Bayer AG Company Detail
11.8.2 Bayer AG Business Overview
11.8.3 Bayer AG Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.8.4 Bayer AG Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.8.5 Bayer AG Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Tardive Dyskinesia (TD) Treatment Drugs Introduction
11.9.4 Sanofi Revenue in Tardive Dyskinesia (TD) Treatment Drugs Business (2019-2024)
11.9.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
